PMGC Holdings Inc. ELAB
1.63 USD -0.02 (-0.98%)
Nov 6, 2026, 11:42 AM EST
1.61 Day range 1.69
1.60 52-week range 1,471.20
- YTD
- -99.54%
- 1 year
- -99.87%
- Market cap
- 1.34M
- Revenue (ttm)
- 2.47M
- Profit margin
- -192.08%
- EPS (ttm)
- -1,748.36
- Shares out
- 3.07M
- YTD return
- -99.54%
- 1-year return
- -99.87%
- Volume
- 16.41K
- Avg volume
- 248.27K
- Open
- 1.64
- Previous close
- 1.65
- Day's range
- 1.61 – 1.69
- 52-week range
- 1.60 – 1,471.20
5D -0.89 (-35.04%)
Key statistics
- Enterprise value
- 569.06K
- PEG ratio
- 0.00
- Price / sales
- 3.24
- Price / book
- 11.81
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 91.30%
- Free cash flow
- -3.57M
- Total cash
- 100.03K
- Total debt
- 140.06K
- Return on equity
- -351.00%
- Short % of float
- 22.28%
- 50-day average
- 7.79
- 200-day average
- 77.01
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ELAB Revenue — quarterly 1.31M
ELAB Net income — quarterly -2.94M
ELAB EPS — quarterly -6.06
About PMGC Holdings Inc.
Elevai Labs Inc., a skincare development company, designs, manufactures, and markets skincare products in the United States. The company offers Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. It serves dermatologists, plastic surgeons, medical spa owners, and physicians focused on aesthetic and therapeutic skincare. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs Inc. was incorporated in 2020 and is based in Newport Beach, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- elevaiskincare.com
News
PMGC Holdings Unit Northstrive Biosciences Completes Preclinical Study Evaluating EL-32 Both As A Standalone Treatment And In Combination With Semaglutide; Study Identifies Preliminary Lean-mass Finding At Highest Dose While Informing Future Preclinical Development Strategy 
NorthStrive Biosciences Announces Results from EL-32 Preclinical Combination Study with Semaglutide and Plans for Next Phase of Development 
PMGC Holdings Registers A Doing-Business-As Name As Northstrive Holdings, And Enters Into A Trademark License Agreement With NorthStrive Companies - PMGC Holdings’ Northstrive Biosciences Executes Statement Of Work With Charles River To Conduct Analytical Characterization Supporting Development Of EL-22 And EL-32 Engineered Probiotic Programs
PMGC Holdings’ Northstrive Amends Development And License Agreement With Yuva Biosciences To Launch Three-Phase Program Advancing Four AI-Discovered Compounds And Updating AI Scope, IP, Field Of Use, And Financial Terms 
12 Consumer Staples Stocks Moving In Thursday's After-Market Session - PMGC Announces 1-For-10 Reverse Stock Split, Effective Aug. 21
PMGC Holdings Confirms It Is In Compliance With Nasdaq’s Newly Approved Market Value Of Listed Securities Continued-Listing Requirement - PMGC Holdings’ A&B Aerospace Enters Into Long-Term Agreement With PAD Group To Manufacture And Supply Precision-Machined Aerospace And Defense Components
- PMGC Holdings Unit NorthStrive Defense Tech Enters Project Services Agreement With Deploy360 For Validation And Testing Of Patented GPS-Denied Autonomous Navigation Technology
Your note
Sign in to keep a note on ELAB — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 0.00% | 12,709 | 33.17K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.00% | 226 | 589 | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.00% | 216 | 563 | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.00% | 196 | 511 | Sep 29, 2024 |
| HRT Financial LP | 0.00% | 179 | 467 | Sep 29, 2024 |
| Diversify Advisory Services, LLC | 0.00% | 125 | 326 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.00% | 226 | 589 | Oct 30, 2024 |